Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LXRX Lexicon Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: LXRX
Price (delayed)
$0.7755
Market cap
$281.64M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.51
Enterprise value
$319.46M
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes
Highlights
The company's EPS rose by 39% YoY and by 19% QoQ
The net income has increased by 12% from the previous quarter and by 8% YoY
Lexicon Pharmaceuticals's quick ratio has plunged by 86% YoY and by 59% from the previous quarter
Lexicon Pharmaceuticals's equity has shrunk by 57% YoY and by 16% QoQ
Key stats
What are the main financial stats of LXRX
Market
Valuations
Earnings
Shares outstanding
363.18M
Market cap
$281.64M
Enterprise value
$319.46M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.28
Price to sales (P/S)
9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.23
Revenue
$31.21M
Gross profit
$30.6M
Operating income
-$177.46M
Net income
-$177.3M
EBIT
-$164.84M
EBITDA
-$164.27M
Free cash flow
-$168.46M
Per share
Balance sheet
Liquidity
EPS
-$0.51
EPS diluted
-$0.51
Free cash flow per share
-$0.47
Book value per share
$0.34
Revenue per share
$0.09
TBVPS
$0.7
Total assets
$297.67M
Total liabilities
$174.64M
Debt
$100.7M
Equity
$123.03M
Working capital
$135.11M
Debt to equity
0.82
Current ratio
2.22
Quick ratio
2.19
Net debt/EBITDA
-0.23
Margins
Efficiency
Dividend
EBITDA margin
-526.3%
Gross margin
98%
Net margin
-568%
Operating margin
-568.6%
Return on assets
-55%
Return on equity
-103.2%
Return on invested capital
-60.3%
Return on capital employed
-88.2%
Return on sales
-528.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LXRX stock price
How has the Lexicon Pharmaceuticals stock price performed over time
Intraday
8.16%
1 week
23.76%
1 month
18.23%
1 year
-55.69%
YTD
5.01%
QTD
68.29%
Financial performance
How have Lexicon Pharmaceuticals's revenue and profit performed over time
Revenue
$31.21M
Gross profit
$30.6M
Operating income
-$177.46M
Net income
-$177.3M
Gross margin
98%
Net margin
-568%
LXRX's net margin has surged by 93% year-on-year and by 12% since the previous quarter
LXRX's operating margin has surged by 93% year-on-year and by 10% since the previous quarter
The net income has increased by 12% from the previous quarter and by 8% YoY
The operating income has grown by 10% since the previous quarter and by 4.6% year-on-year
Price vs fundamentals
How does LXRX's price correlate with its fundamentals
Growth
What is Lexicon Pharmaceuticals's growth rate over time
Valuation
What is Lexicon Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.28
P/S
9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.23
The company's EPS rose by 39% YoY and by 19% QoQ
Lexicon Pharmaceuticals's equity has shrunk by 57% YoY and by 16% QoQ
The P/B is 36% lower than the 5-year quarterly average of 3.3 but 6% higher than the last 4 quarters average of 2.0
LXRX's price to sales (P/S) is 99% less than its 5-year quarterly average of 942.2 and 87% less than its last 4 quarters average of 66.2
Efficiency
How efficient is Lexicon Pharmaceuticals business performance
The company's return on sales has surged by 93% YoY and by 11% QoQ
LXRX's ROA is up by 12% YoY and by 3.2% QoQ
The company's return on equity fell by 10% QoQ but it rose by 6% YoY
LXRX's ROIC is up by 4.9% YoY but it is down by 3.6% from the previous quarter
Dividends
What is LXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LXRX.
Financial health
How did Lexicon Pharmaceuticals financials performed over time
The total assets is 70% greater than the total liabilities
Lexicon Pharmaceuticals's quick ratio has plunged by 86% YoY and by 59% from the previous quarter
The current ratio has plunged by 86% YoY and by 59% from the previous quarter
LXRX's debt is 18% smaller than its equity
Lexicon Pharmaceuticals's debt to equity has surged by 128% YoY and by 19% QoQ
Lexicon Pharmaceuticals's equity has shrunk by 57% YoY and by 16% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.